Hypereosinophilic Syndrome News and Research

RSS
Hypereosinophilic syndrome is a condition characterized by a persistently elevated eosinophil count (= 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow.
Non-coding RNAs play key role in maintaining proper balance between fighting infection and inflammation

Non-coding RNAs play key role in maintaining proper balance between fighting infection and inflammation

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Knopp and NIAID collaborate to investigate eosinophil-lowering effects of dexpramipexole

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation

Three different leukemias are all caused by mutations that alter a specific enzyme controlling blood cell proliferation